Access more affordable Valganciclovir through the MPP

On August 5 2013, The Medicines Patent Pool (MPP) announced an agreement with Swiss pharmaceutical company Roche to increase access to valganciclovir, an important easy-to-take oral medicine to treat cytomegalovirus (CMV). CMV is a viral infection that can cause blindness in people living with HIV. The agreement’s first stage is a price reduction that will significantly improve access to Roche‚Äôs valganciclovir for people living with HIV in 138 developing countries by making it up to 90% cheaper than current prices. Learn how to access these prices here.

Comments are closed.